Literature DB >> 8350416

Evidence that the structural conformation of envelope gp120 affects human immunodeficiency virus type 1 infectivity, host range, and syncytium-forming ability.

L Stamatatos1, C Cheng-Mayer.   

Abstract

We investigated how amino acid changes within and outside the V3 loop of the envelope glycoprotein of human immunodeficiency virus type 1 influence the infectivity, host range, and syncytium-forming ability of the virus. Our studies show that on the genomic backgrounds of the human immunodeficiency virus type 1 strains SF2 and SF13, a reciprocal exchange of full-loop sequences does not alter the syncytium-forming ability of the viruses, indicating that a determinant(s) for this biological property maps outside the loop. However, specific amino acid substitutions, both within and outside the V3 loop, resulted in loss of infectivity, host range, and syncytium-forming potential of the virus. Furthermore, it appears that a functional interaction of the V3 loop with regions in the C2 domain of envelope gp120 plays a role in determining these biological properties. Structural studies of mutant glycoproteins show that the mutations introduced affect the proper association of gp120 with the transmembrane glycoprotein gp41. Our results suggest that mutations that alter the structure of the V3 loop can affect the overall conformation of gp120 and that, reciprocally, the structure of the V3 loop is influenced by the conformation of other regions of gp120. Since the changes in the replicative potential, host range, and fusogenic ability of the mutant viruses correlate well with the changes in gp120 conformation, as monitored by the association of gp120 with gp41, our results support a close relationship between envelope gp120 structural conformation and the biological phenotype of the virus.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8350416      PMCID: PMC237967     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity.

Authors:  L A Ivanoff; J W Dubay; J F Morris; S J Roberts; L Gutshall; E J Sternberg; E Hunter; T J Matthews; S R Petteway
Journal:  Virology       Date:  1992-04       Impact factor: 3.616

2.  Generation of hybrid human immunodeficiency virus utilizing the cotransfection method and analysis of cellular tropism.

Authors:  A Velpandi; T Nagashunmugam; S Murthy; M Cartas; C Monken; A Srinivasan
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

3.  Identification of conserved residues in the human immunodeficiency virus type 1 principal neutralizing determinant that are involved in fusion.

Authors:  E O Freed; R Risser
Journal:  AIDS Res Hum Retroviruses       Date:  1991-10       Impact factor: 2.205

4.  Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity.

Authors:  K A Page; S M Stearns; D R Littman
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

5.  Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo.

Authors:  P Westervelt; D B Trowbridge; L G Epstein; B M Blumberg; Y Li; B H Hahn; G M Shaw; R W Price; L Ratner
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

6.  Mutations in the principal neutralization determinant of human immunodeficiency virus type 1 affect syncytium formation, virus infectivity, growth kinetics, and neutralization.

Authors:  R J Grimaila; B A Fuller; P D Rennert; M B Nelson; M L Hammarskjöld; B Potts; M Murray; S D Putney; G Gray
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 envelope glycoprotein molecules containing membrane fusion-impairing mutations in the V3 region efficiently undergo soluble CD4-stimulated gp120 release.

Authors:  E A Berger; J R Sisler; P L Earl
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

8.  Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism.

Authors:  B Chesebro; K Wehrly; J Nishio; S Perryman
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

9.  Lack of correlation between soluble CD4-induced shedding of the human immunodeficiency virus type 1 exterior envelope glycoprotein and subsequent membrane fusion events.

Authors:  M Thali; C Furman; E Helseth; H Repke; J Sodroski
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

10.  Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding.

Authors:  Q J Sattentau; J P Moore
Journal:  J Exp Med       Date:  1991-08-01       Impact factor: 14.307

View more
  37 in total

1.  A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences.

Authors:  Mark A Jensen; Mia Coetzer; Angélique B van 't Wout; Lynn Morris; James I Mullins
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

2.  Fold recognition of the human immunodeficiency virus type 1 V3 loop and flexibility of its crown structure during the course of adaptation to a host.

Authors:  Teruaki Watabe; Hirohisa Kishino; Yoshiyasu Okuhara; Yasuhiro Kitazoe
Journal:  Genetics       Date:  2005-12-15       Impact factor: 4.562

3.  Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies.

Authors:  J P Moore; F E McCutchan; S W Poon; J Mascola; J Liu; Y Cao; D D Ho
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

4.  Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding.

Authors:  L Stamatatos; C Cheng-Mayer
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

5.  Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: evidence for multiple pathways.

Authors:  B A Watkins; M S Reitz; C A Wilson; K Aldrich; A E Davis; M Robert-Guroff
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

6.  The CD4-independent tropism of human immunodeficiency virus type 2 involves several regions of the envelope protein and correlates with a reduced activation threshold for envelope-mediated fusion.

Authors:  J D Reeves; T F Schulz
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

7.  CCR5 coreceptor utilization involves a highly conserved arginine residue of HIV type 1 gp120.

Authors:  W K Wang; T Dudek; Y J Zhao; H G Brumblay; M Essex; T H Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

8.  Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein.

Authors:  J P Moore; J Sodroski
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

9.  Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures.

Authors:  W A O'Brien; S H Mao; Y Cao; J P Moore
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

10.  Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.

Authors:  D Noah Sather; Jakob Armann; Lance K Ching; Angeliki Mavrantoni; George Sellhorn; Zachary Caldwell; Xuesong Yu; Blake Wood; Steve Self; Spyros Kalams; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.